Flex Pharma, Inc.
Flex Pharma, Inc. is listed today as Decoy Therapeutics Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2023 | $6 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Apr 2022 | $2 M | Private placement after listing | $2 to $10 million | options | SEC | |
| Jul 2014 | $16 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Flex Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (May 2023).
SEC Form D · May 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · May 2023
That is all the official record says: Flex Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Flex Pharma, Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Barbara Louise Hibner | Person | not stated | not stated | Held Series A preferred stock (Form 3, 2025) | SEC Form 3 |
| Frederick Pierce II | Person | not stated | not stated | Held Series A preferred stock (Form 3, 2025) | SEC Form 3 |
| Longwood Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Peter Barton Hutt | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Peter Klaus Marschel | Person | not stated | not stated | Held Series A preferred stock (Form 3, 2025) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 20 investors.
Largest shareholders today
Institutions holding Decoy Therapeutics Inc. shares, as of Sep 30, 2026.
- Commonwealth Equity Services, LLC$0 M1.34%
- UBS Group AG$0 M0.19%
- Vanguard Capital Management LLC$0 M0.17%
- Tower Research Capital LLC (TRC)$0 M0.16%
- SBI Securities Co., Ltd.$0 M0.00%
- Jpmorgan Chase & Co$0 M0.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David J. Arthur | President, Chief Executive Officer, Director | May 2023 |
| Mark J. Rosenblum | Chief Financial Officer | May 2023 |
| Christoph Westphal | Executive officer | Aug 2014 |
| Arnold C. Hanish | Director | May 2023 |
| Bruce J. McCreedy | Director | May 2023 |
| David J. Arthur | President, Chief Executive Officer, Director | May 2023 |
| Jonathan C. Lieber | Director | May 2023 |
| Paul C. Lammers | Director | May 2023 |
| Tess Burleson | Director | May 2023 |
| William K. McVicar | Chair | May 2023 |
| Jonathan J. Lieber | Director | May 2022 |
| Tess K. Burleson | Director | May 2022 |
| Christoph Westphal | Director | Aug 2014 |
| Peter Barton Hutt | Director | Aug 2014 |
| Stephen Barton Kraus | Director | Aug 2014 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.